Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Purpose: Existing biomarkers including C-reactive protein (CRP) do not adequately distinguish active and inactive TAK. We compared serum p-glycoprotein (p-gp)/Multidrug Resistance Protein 1 (MDR1), monomeric CRP (mCRP), CRP, and mCRP:CRP ratio in Takayasu arteritis (TAK) and healthy controls and their relationship with disease activity.

Patients And Methods: Serum p-gp mCRP (ELISA) and CRP (nephelometry) were compared between consecutive adults with TAK (>18 years) enrolled from a prospective cohort (n = 92) and healthy controls (n = 29), and between active vs inactive TAK (n = 46 each). In a subset of active immunosuppressive-naïve TAK (n = 29), correlation was assessed between serum p-gp and p-gp expression on circulating T helper lymphocyte populations: overall (CD4+), Th17 (CD4+IL-17+), Th17.1 (CD4+IL-17+IFN-γ+) lymphocytes [normalized to Tregs (CD4+CD25+FoxP3+)]. Changes in serum p-gp, mCRP, CRP, and mCRP:CRP were compared before and after immunosuppression (n = 29). Data was represented using median (Q1-Q3). Receiver operating characteristics (ROC) curves were generated for TAK vs controls, and active vs inactive TAK with serum p-gp, mCRP, CRP, and mCRP:CRP. Multivariable-adjusted linear regression was used to predict active disease with serum p-gp, mCRP, CRP, or mCRP:CRP.

Results: Serum p-gp (11.19 vs 8.05 ng/mL), mCRP (1.61 vs 1.25 µg/L), and CRP (5.40 vs 2.1 mg/L) were elevated in TAK vs controls (p <0.05 for all). CRP was higher and mCRP:CRP ratio was lower in active vs inactive TAK (p < 0.001). ROC curves identified moderate prediction for active disease with CRP and inactive disease with serum p-gp (area under ROC curve 0.705 and 0.392, respectively). Multivariable-adjusted linear regression confirmed association of CRP with active disease (p = 0.009) and serum p-gp with inactive disease (p = 0.041). In treatment-naïve TAK, serum p-gp negatively correlated with p-gp+Th17.1 lymphocytes (Spearman's rho=-0.39, p = 0.046). CRP and serum p-gp were significantly lowered following immunosuppressive therapy in treatment-naïve TAK (p < 0.05).

Conclusion: Serum p-gp and mCRP are elevated in TAK. Serum p-gp is associated with inactive disease.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11566576PMC
http://dx.doi.org/10.2147/JIR.S490958DOI Listing

Publication Analysis

Top Keywords

serum p-gp
24
mcrp crp
16
p-gp mcrp
16
active inactive
12
inactive tak
12
crp mcrpcrp
12
serum
8
serum p-glycoprotein
8
c-reactive protein
8
takayasu arteritis
8

Similar Publications

Surface functionalized albumin nanoparticles of palbociclib with amplified brain delivery for treating brain glioblastoma.

Sci Rep

August 2025

Department of Pharmaceutical Chemistry, College of Pharmaceutical Sciences, Dayananda Sagar University, Harohalli, Kanakapura Road, Bengaluru, 562112, India.

Glioblastoma multiforme (GBM) has a global occurrence of 0.59 to 3.69 per one lakh people.

View Article and Find Full Text PDF

Poor adherence to oral bisphosphonate therapy remains a major challenge in the treatment of osteoporosis, substantially reducing therapeutic efficacy. While reminder interventions have been proposed as a method to enhance adherence, evidence remains limited. This study aimed to evaluate the impact of written and verbal reminders on medication adherence compared to standard patient care over a 12-month period in a real-world clinical setting.

View Article and Find Full Text PDF

Objective: The clearance of digoxin in obese patients with renal impairment is reduced, leading to elevated serum concentrations and increased risks of digoxin toxicity. However, the exact mechanism of such alterations in obese patients remains unclear. Previous studies have suggested that the organic anion transport-ing polypeptide 4c1 (Oatp4c1, Slco4c1) mediates the elimination of digoxin at the basal membrane of the proximal tubule (PT), indicating its potential role in the pharmacokinetic changes in obese patients.

View Article and Find Full Text PDF

Colorectal cancer (CRC) remains a leading cause of cancer-related mortality, driven by complex interactions between inflammatory pathways, gut microbiota dysbiosis, and tumor microenvironment remodeling. Conventional therapies, particularly single-target oral chemotherapeutics, are hindered by poor bioavailability, systemic toxicity, and drug resistance. To address these limitations, we engineered KGM-PTX/CSM microspheres, a dual-responsive drug delivery system leveraging the elevated reactive oxygen species (ROS) in CRC and β-mannanase overexpression in the colorectum.

View Article and Find Full Text PDF

Enantioselective transplacental transfer of xenobiotics: mechanisms, plasma protein binding, and health implications for fetal development.

Arch Toxicol

September 2025

ZJP Key Laboratory of Pollution Exposure and Health Intervention, Interdisciplinary Research Academy (IRA), Zhejiang Shuren University, Hangzhou, 310015, China.

The transplacental transfer of xenobiotics, particularly in an enantioselective manner, is a critical and evolving area of developmental toxicology. Pregnant women, as a highly vulnerable population, are frequently exposed to pervasive chiral chemicals that can cross the placenta, with the placenta serving as an enantioselective barrier. Despite significant research on enantioselective transfer of xenobiotics using various models (in vivo, ex vivo, and in vitro), a comprehensive understanding of the underlying mechanisms of xenobiotics-plasma protein binding remains lacking.

View Article and Find Full Text PDF